Search Orphan Drug Designations and Approvals
-
Generic Name: | 225Ac-lintuzumab |
---|---|
Date Designated: | 11/25/2014 |
Orphan Designation: | Treatment of acute myelogenous leukemia |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Actinium Pharmaceuticals, Inc. 379 Thornall Avenue 6th Floor Edison, New Jersey 08837 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-